Immunotherapy in Locally Advanced HNSCC: Is There Still Room for New Agents?

Why It Matters

The approvals validate peri‑operative immunotherapy but still exclude a substantial patient segment, highlighting a clear market need for therapies that address non‑surgical, elderly, and PD‑L1‑low populations.

Key Takeaways

• FDA approved Keytruda for resectable LA HNSCC with PD‑L1 CPS ≥1
• 63,000 LA HNSCC cases diagnosed in 2024 across six major markets
• 40% of patients receive definitive chemoradiotherapy, remaining outside current IO trials
• Patients ≥65 years will be 44% of the market by 2034
• Pembrolizumab shows limited benefit in hypopharyngeal and older subgroups

Pulse Analysis

The 2025 FDA clearance of pembrolizumab for resectable LA HNSCC marks the first peri‑operative immunotherapy indication in head‑and‑neck cancer. KEYNOTE‑689 demonstrated a reduction in distant recurrence when Keytruda was used as neoadjuvant monotherapy followed by adjuvant radiotherapy with or without cisplatin, prompting the regulatory milestone. Simultaneously, the GORTEC‑sponsored NIVOPOSTOP trial reported meaningful adjuvant benefits with nivolumab, though a formal filing is still pending. Together these studies have shifted the treatment paradigm, yet they address only the surgical pathway, which represents roughly 60% of the diagnosed 63,000 patients in 2024 across the United States, France, Germany, Italy, Spain and the United Kingdom.

A sizable unmet need persists among the 40% of LA HNSCC patients managed non‑surgically with definitive chemoradiotherapy, a cohort that current trials deliberately exclude. Moreover, demographic trends indicate that patients aged 65 and older—who already account for 39% of cases—will rise to 44% by 2034, and subgroup analyses suggest attenuated pembrolizumab efficacy in this group. Approximately 14% of the disease population expresses PD‑L1 CPS < 1, rendering them ineligible for Keytruda but potentially responsive to nivolumab or future agents. These gaps underscore a market ripe for therapies that can integrate with or replace existing chemoradiation regimens, especially for organ‑preserving strategies.

Strategically, developers can pursue combination approaches that marry the distant‑recurrence control of pembrolizumab with agents targeting locoregional disease, a primary driver of morbidity. Cisplatin‑sparing regimens, novel checkpoint inhibitors, or targeted therapies could fill the efficacy void in older, PD‑L1‑low, and non‑surgical patients. With a projected increase in the elderly HNSCC population and a clear regulatory precedent for peri‑operative immunotherapy, the commercial upside for new agents is substantial, offering both differentiation and the potential to capture a large share of an expanding market.